Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: FAK/VEGFR3 inhibitors - CureFAKtor Pharmaceuticals

Next Previous
Drug Profile

Research programme: FAK/VEGFR3 inhibitors - CureFAKtor Pharmaceuticals

Alternative Names: C10; C9; C9A; CFAK-C10; CFAK-C4; CFAK-C9; CFAK-C9a; CFAK-Y15; Chloropyramine; Chloropyramine hydrochloride; FAK inhibitors - CureFAKtor; FAK technology platform - CureFAKtor; Y15

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CureFAKtor Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pancreatic cancer; Solid tumours

Most Recent Events

  • 03 May 2016 No recent reports on development identified - Preclinical for Solid tumours and Pancreatic cancer in USA (PO)
  • 14 Nov 2011 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011) ,,
  • 23 Jun 2011 Pharmacodynamics data from a preclinical trial in Pancreatic cancer presented at the 16th European Cancer Conference and the 36th Congress of the European Society for Medical Oncology (ECCO/ESMO-2011)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top